Business
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA
TOKYO & HYOGO, Japan, May 07, 2025--MEDIPAL and JCR announced that the U.S. FDA granted orphan drug designation (ODD) to JR-446, an investigational drug for the treatment of MPS IIIB.
About this update from Jcr Pharmaceuticals Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/fb9a53737e1a3022188b1be2d94590e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x1dDkqpZ664TCn8hwpV0zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fb9a53737e1a3022188b1be2d94590e0","width":480,"height":251}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/3f8e434dd06586c790c92b8ed9836d82"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GH3FcvyZwyDmafwlMiyb_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3f8e434dd06586c790c92b8ed9836d82","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/O5XCFWDyLBY4tMDeRAnlyQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/3f8e434dd06586c790c92b8ed9836d82","width":1024,"height":512}}},{"type":"text","content":"TOKYO & HYOGO, Japan, May 07, 2025--(BUSINESS WIRE)--MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to JR-446, an investigational drug for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB or Sanfilippo syndrome type B).","length":388,"tagName":"p"},{"type":"text","content":"MPS IIIB affects an estimated 500 to 1,000 individuals worldwide,1 causing severe central nervous system (CNS) symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR’s proprietary J-Brain Cargo® technology, has shown promising non-clinical results in addressing the CNS symptoms of this challenging disorder, and is currently being studied in a Phase I/II trial that is being conducted in Japan (JR-446-101) under a collaboration agreement between the two companies.","length":545,"tagName":"p"},{"type":"text","content":""We are extremely pleased that JR-446 has received orphan drug designation from the...